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NAD metabolites interfere with
proliferation and functional
properties of THP-1 cells
Katharina Petin1, Ronald Weiss1 , Gerd Müller2,
Antje Garten3,4, Anja Grahnert1, Ulrich Sack1 and
Sunna Hauschildt5
Abstract
Over the past few years the NAD-related compounds nicotinamide (NAM), nicotinamide riboside (NR) and 1-methyl-
nicotinamide (MNA) have been established as important molecules in signalling pathways that contribute to metabolic
functions of many cells, including those of the immune system. Among immune cells, monocytes/macrophages, which are
the major players of inflammatory processes, are especially susceptible to the anti-inflammatory action of NAM. Here we
asked whether NAM and the two other compounds have the potential to regulate differentiation and LPS-induced bio-
logical answers of the monocytic cell line THP-1. We show that treatment of THP-1 cells with NAM, NR and MNA
resulted in growth retardation accompanied by enrichment of cells in the G0/G1-phase independent of p21 and p53. NAM
and NR caused an increase in intracellular NAD concentrations and SIRT1 and PARP1 mRNA expression was found to be
enhanced. The compounds failed to up-regulate the expression of the cell surface differentiation markers CD38, CD11b
and CD14. They modulated the reactive oxygen species production and primed the cells to respond less effectively to the
LPS induced TNF-a production. Our data show that the NAD metabolites interfere with early events associated with
differentiation of THP-1 cells along the monocytic path and that they affect LPS-induced biological responses of the cell line.
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Introduction
Nicotinamide (NAM) and nicotinic acid belong to the
vitamin B3 group, also known as niacin.1 There is
increasing evidence that NAM, a natural occurring
compound of the human diet, can be used as a poten-
tial therapeutic drug to treat numerous diseases such as
metabolic and immunological disorders.2,3
In most mammalian cells, NAM is the predominant
precursor of NAD, a molecule playing a key role in
energy metabolism and electron transfer. NAD and its
reduced form NADH function as cofactors in multiple
redox reactions. Electrons derived fromNADH are trans-
ferred to O2 to generate ATP. Unlike NAD-dependent
redox reactions, NAD-dependent signalling processes
are catalysed by enzymes that continuously consume
NAD. NAD-degrading enzymes regulate various
biological processes, such as transcription, cell cycle pro-
gression, DNA repair and intracellular communication.4,5
Enzymatic cleavage of NAD, which is catalysed
by CD38, ADP-ribosyltransferases (ARTs),
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poly(ADP-ribose) polymerases (PARPs) and sirtuins,
results in the release of NAM and the ADP-ribose
moiety (ADPR). While NAM serves as a feedback inhib-
itor of these enzymes,6,7 ADPR is transferred onto an
acceptor or used to facilitate Ca2þ influx.8 To maintain
normal tissue levels of NAD and to relieve NAM inhi-
bition of NAD-consuming enzymes, a salvage pathway
recycles NAM back to NAD (Figure 1). Nicotinamide
phosphoribosyltransferase (NAMPT), the first enzyme in
this pathway, catalyses the production of nicotinamide
mononucleotide (NMN) from NAM and phosphoribo-
syl pyrophosphate (PRPP). In a second step, NMN
together with ATP is then used by nicotinamide mono-
nucleotide adenylyltransferases (NMNAT 1-3) to yield
NAD.9 Only recently nicotinamide riboside (NR), a nat-
ural product found in milk, has also been identified as a
NAD precursor.10 NR is metabolised to NMN, which in
turn is converted into NAD, a reaction catalysed by
NMNAT 1-3 (Figure 1). Apart from being recycled to
NAD, NAM is irreversibly methylated by nicotinamide-
N-methyltransferase (NNMT) to yield 1-methylnicotina-
mide (MNA).11 MNA serves as a substrate of aldehyde
oxidase 1 (AOX1) to generate N-methyl-2-pyridone-5-
carboxamide (2PY) as well as N-methyl-4-pyridone-3-
carboxamide (4PY) and hydrogen peroxide which, at
low physiological concentrations, has been suggested to
exert lifespan extending effects.11 Considering the crucial
role of NAD in regulating metabolic processes, much
attention has been paid to the use of the NAD precursors
NAM and NR,3,10,12–15 and the NAD degradation prod-
uct MNA,16 as agents for therapeutic intervention. These
are partly based on the well described anti-inflammatory
effects of NAM and NR.7,17–19 In contrast, little is
known about a role of NAD metabolites in regulating
differentiation of myeloid leukaemia cells such as HL60,
U937 and THP-1. When exposed to vitamin D3 (VitD),
these cells undergo a cell cycle arrest and express surface
markers of monocytic cells including CD38,20 CD11b
and CD14.21–23
CD38 is a type II glycoprotein that transforms NAD
into cyclic ADP-ribose (cADPR), a powerful mobiliser
of intracellular Ca2þ.24,25 During differentiation, mye-
loid cells strongly up-regulate CD38 expression and
there is some evidence that CD38 and the consequen-
tial accumulation of cADPR play a causal role in medi-
ating differentiation.26 In addition to CD38, CD11b is
another classical marker of monocyte differentiation.27
CD11b associated with CD18, is involved in cell adhe-
sion and functions as a complement receptor and part
of the multimeric LPS-receptor complex.28,29 CD14
binds LPS and transfers it to myeloid differentiation
factor 2 (MD2) to initiate TLR4 dimerisation and sig-
nalling. Its expression has been shown to increase dra-
matically during the differentiation of monocytic
precursors into monocytes.21–23
In the present study, we asked whether the NAD
related compounds NAM, NR and MNA induce cellu-

















Figure 1. Intracellular NAD metabolism. NAM is a product of deacetylation and ADP-ribosylation reactions, which are catalysed by
NAD-consuming enzymes such as sirtuins, PARPs, ARTs and CD38. NAMPT, the rate-limiting step in the NAD salvage pathway,
catalyses the formation of NMN from NAM and 50-phosphoribosyl-1-pyrophosphate. NMN is then converted into NAD by NMNAT
1-3. NAM can also be methylated by NNMT leading to the formation of 1-MNA. NR enters the NAD biosynthesis pathway by
phosphorylation to NMN, a step catalysed by NRKs. Other NAD biosynthesis pathways include the de novo synthesis starting from
tryptophan and the Preiss–Handler route by which nicotinic acid enters the de novo pathway.
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properties of THP-1 cells. We identified all three com-
pounds as agents with anti-proliferative effects that, to a
limited extend, are able to induce THP-1 cells to differ-
entiate along the monocytic path. They prime the cells to
modulate the release of reactive oxygen species (ROS)
and to suppress LPS-induced TNF-a production, most
likely in a CD14- and TLR4-independent manner.
Material and methods
Reagents
NAM, MNA and resveratrol were purchased form
Sigma-Aldrich (Taufkirchen, Germany), NR from
ChromaDex (Irvine, CA, USA) and VitD (1,25-
(OH)2-D3) from Cayman Chemical (Ann Arbor, MI,
USA). VitD was dissolved in 40% ethanol (stock solu-
tion of 2.5 mM), resveratrol in DMSO (stock solution 5
mg/ml), NAM in distilled water (stock solution 1M) or
NR and MNA in media (stock solution 1M each).
Cell culture
THP-1 cells were cultured in RPMI 1640 (contains
0.008 mM NAM; GE Healthcare, Little Chalfont,
UK) supplemented with 10% FCS (Sigma-Aldrich),
1% penicillin (10,000 U/ml) and streptomycin (10,000
mg/ml) (Seromed Biochrom KG, Berlin, Germany) and
0.05 mM 2-mercaptoethanol (Life Technologies,
Darmstadt, Germany). Cells (0.2 106/ml) were
treated in a humidified atmosphere of 5% CO2
at 37C with 8 mM NAM, 8 mM NR, 3.2 mM
MNA, 0.1 mM VitD and the corresponding solvent
controls for several times (24–96 h). The cell
numbers were counted with a Neubauer chamber and
the viability was determined by trypan blue (Sigma-
Aldrich) exclusion.
Detection of apoptosis/necrosis
Apoptosis and necrosis of THP-1 cells were determined
using a FITC Annexin V/PI kit (BioLegend, San
Diego, CA, USA) according to the manufacturer’s
instruction. Analyses were performed using a FACS
Canto II flow cytometer (Becton Dickinson, Franklin
Lakes, NY, USA).
Determination of intracellular total NAD
Cells (2 106) were harvested by centrifugation (400g,
6 min, room temperature (RT)). The pellet was re-
suspended in 200 ll 1 M perchloric acid and homoge-
nised by sonication (3 strokes, output 30%, Bandelin
Sonopuls GM70, Bandelin, Berlin, Germany). After
centrifugation (18,000g, 5 min, 4C) the pellet of each
sample was used for protein determination (Bio-Rad
DC Protein Assay, Hercules, CA, USA).
Supernatants were neutralised with 3M potassium car-
bonate, centrifuged again (18,000g, 10 min, 4C) and
frozen at 80C. NAD concentrations (NAD plus oxi-
dised NADH) were determined by HPLC analysis, as
described previously.30,31 The NAD levels were nor-
malised to the total protein content.
Detection of cell surface markers
After 96 h THP-1 cells were harvested by centrifuga-
tion (400g, 6 min, RT). Cells (1.5 105) were incubated
at 4C with 10% human AB-serum (Institute of
Transfusions Medicine, University Hospital Leipzig)
to saturate Fc receptors and block unspecific bindings.
After 15 min the cells were washed (PBSþ 10% Emagel
(Pirmal Healthcare, Morpeth, Northumberland,
UKþ 0.1% NaN3)) and the direct dye labelled Abs
anti-CD14-APC (BioLegend), anti-TLR4-PE (R&D
systems, Minneapolis, MO, USA) or the non-labelled
anti-CD11b (BL-M/G1), anti-CD14 (BL-M/G14) and
anti-CD38 (BL-AC38) Abs (all from DiaMak, Leipzig,
Germany) as well as the corresponding isotypes were
added for 20 min at 4C. Cells were then washed and
the non-labelled probes further incubated for 15 min
with a FITC-labelled goat-anti-mouse Ab. After wash-
ing and fixation the cells were analysed on a FACS
Canto II flow cytometer (Becton Dickinson). For
data analysis median fluorescence intensity (MFI)
values of the isotype were subtracted from MFI
values of the sample.
Detection of TNF-a in supernatants
THP-1 cells (1 106/ml) were cultured for 96 h before
they were incubated in the presence and absence of 100
ng/ml LPS (Escherichia coli, serotype 055:B5, Sigma-
Aldrich) for 4 h. TNF-a levels in the supernatants were
determined using a commercially available ELISA-
based assay system (PeproTech, Rocky Hill, NJ,
USA) according to the manufacturer’s protocol.
Detection of intracellular ROS
THP-1 cells cultured for 96 h were harvested by centri-
fugation (400g, 6 min, RT). Cells (1.5 105) were re-
suspended in 250 ml PBS and incubated for 30 min at
37C, 5% CO2 before 100 ng/ml LPS and 20 mM 20,70-
dichlorodihydrofluorescein diacetate (DCF-DA)
(Sigma-Aldrich) were added. After 30 min intracellular
ROS production was measured by oxidation of intra-
cellular fluorescent DCF-DA by flow cytometry on a
FACS Canto II flow cytometer (Becton Dickinson).
The shift in fluorescence intensity was used to assess
the percentage of cells that were able to generate ROS.
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Gates to determine positive cells were set to exclude
95% of control cells.
Cell cycle analyses
THP-1 cells were harvested after 96 h by centrifugation
(400g, 6 min, RT). Cells (1 106) were re-suspended in
0.5 ml PBS/EDTA and fixed by addition of 1.5 ml ice-
cold ethanol. After centrifugation, the cells were re-
suspended in PBS/EDTA treated with 10 mg/ml
RNase A (Life Technologies) and passed through a
cell filter (30 mm). Cell cycle analysis was performed
by flow cytometry on a FACS Canto II flow
cytometer (Becton Dickinson) 15 min after the addition
of 100 mg/ml propidium iodide (PI).
Western blot analysis
Western blot analysis was carried out as described pre-
viously.32 THP-1 cells (1 106) were suspended in RIPA
buffer (50 mM Tris, 150 mM NaCl, 1% Nonidet P 40,
0.5% deoxycholate, 0.1% SDS; pH 7.5) supplemented
with cOmpleteTM EDTA-free protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany). After soni-
cation, the samples were centrifuged for 5 min at
15,000g and 4C. The protein concentrations in the
supernatants were determined using a detergent compat-
ible protein assay (DCTM protein assay, Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s
protocol. Cell lysates (20 mg) boiled in 1 Laemmli
sample buffer were run on a 12% SDS-polyacrylamide
gel (Protean II, Bio-Rad GmbH) and transferred to pol-
yvinylidene difluoride (PVDF) membranes (Amersham
Biosciences, Munich, Germany). Membranes were
probed with anti-SIRT1 Ab (C14H4, 1:1000, Cell
Signaling, Frankfurt am Main, Germany), anti-PARP1
Ab (46D11, 1:1000, Cell Signaling) and anti-b-actin Ab
(AC74, 1:2000, Sigma-Aldrich). The following POD-
conjugated secondary Abs were used: goat-anti-rabbit
IgG Ab (1:2000, Cell Signaling) or goat-anti-mouse
IgG Ab (1:8000, Sigma-Aldrich).
Chemiluminescent detection was achieved by using
the ECL-A/ECL-B reagents (both from Sigma Aldrich)
and the Luminescent Image Analyzer Stella (raytest,
Straubenhardt, Germany).
RNA isolation, reverse transcription and real-time
PCR (qPCR)
Total RNA was isolated from THP-1 cells (1 106)
using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instruction.
DNase I treatment and reverse transcription were per-
formed as previously described.32 Real-time PCR was
performed using the following reaction mixture: 7.5 ml
SYBR Green PCR mastermix (Bio-Rad), 250 nM
forward and reverse primers (see below) and 1.5 ml of
cDNA template in a final volume of 15 ml. The follow-
ing primers were used for the qPCR:
GNB2L1 fwd 50-GAGTGTGGCCTTCTCCTCTG-30
rev 50-GCTTGCAGTTAGCCAGGTTC-30








The reactions were performed as previously
described,32 using GNB2L1 and U6 as the refer-
ence genes.
Statistical analyses
All statistical analyses were performed using SigmaPlot
software (Systat Software GmbH, Erkrath, Germany).
Statistical significance was calculated with the paired
Student’s t-test and classified as follows: *P  0.05;
**P  0.01; ***P  0.001.
Results
NAD metabolites inhibit proliferation of THP-1 cells
To assess the influence of the NAD metabolites NAM
(8 mM), NR (8 mM) and MNA (3.2 mM) on the
growth of THP-1 cells, the cells were counted 24 h,
48 h, 72 h and 96 h after exposure to the compounds.
Concentrations exceeding 8 mM (NAM, NR) or 3.2
mM (MNA) strongly reduced the viability of cells
(data not shown). Of the three compounds tested,
NAM was most effective in reducing cell growth fol-
lowed by NR and MNA (Figure 2a). The cell numbers
determined after 96 h were diminished by 40%, 31%
and 12%, respectively (Figure 2a). A loss of cell viabil-
ity as judged by annexin V/ PI staining could be exclud-
ed (Figure 2b). The reduction in cell growth induced by
NAM was similar to that seen after treatment with
VitD (Figure 2a insert), a vitamin well known to regu-
late differentiation and proliferation of human myelo-
blastic leukaemia cells.20,33,34
NAM, NR and MNA influence the cell cycle
progression
Based on the observation that the NAD derivatives
lead to reduced proliferation rates of THP-1 cells, we
analysed the influence of these compounds on cell cycle
progression. The cells were synchronised in G0/G1 by
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serum deprivation for 48 h. Simultaneous to the treat-
ment with NAM, NR and MNA, cells were stimulated
to re-enter the cell cycle by serum addition and DNA
amounts were analysed after 24 h and 48 h. Serum
deprivation led to an enrichment of cells in G0/G1-
phases (Figure 3a). Addition of serum for 24 h and
48 h caused a significant decrease in G0/G1 cells.
Exposure to NAM in parallel to serum re-stimulation
resulted in an enrichment of cells in G0/G1 and in an
equivalent decrease in S-phase, indicating that NAM
caused the cells to undergo a G0/G1 cell cycle arrest or
a prolonged G1-phase. Similar but less distinct effects
were observed in response to NR and MNA
(Figure 3b).
Stress-induced arrest of eukaryotic cells is often
mediated by accumulation of the transcription factor
and tumour suppressor p53, which results in an
increased transcription of the CDKN1A gene. This
gene encodes for the cyclin dependent kinase (CDK)
inhibitor p21WAF1/CIP1, a potent mediator of cell cycle
arrest.35 Thus, we next tested whether expressions of
p53 and p21 were increased by NAM. We did not
detect any p53 or p21 protein expression neither in
unstimulated nor in NAM-treated cells (data not
shown). Furthermore, CDKN1A/p21 mRNA expres-
sion was not activated in response to NAM
(Supplementary Figure 1). These findings indicate
that accumulation of NAM-treated cells in the G0/
G1-phase is p53 and p21-independent.
We next tested the effect of NAM on the cell cycle
distribution of THP-1 cells stimulated with the sirtuin
activator resveratrol.36 Sirtuins are NAD-dependent
histone-deacetylases that regulate the passage of
eukaryotic cells through the cell cycle. Furthermore,
NAM has been described as an inhibitor of sirtuins.37
As shown in Figure 4, exposure to resveratrol for 48
h resulted in a decrease in G0/G1 positive cells, con-
comitant with an equivalent increase of cells in S-phase.
In the presence of resveratrol alone and together with
NAM, a similar percentage of cells was found in
G0/G1- and S-phase, while in the absence of NAM,
more cells had entered G2/M-phase. Thus, these data
suggest that resveratrol overcomes the NAM-induced
growth retardation.
NAM and NR enhance intracellular NAD
concentrations
Next, we asked whether the general perception that
intracellular NAD is synthesised from NAM and NR
applies to the here described cell system.10,38 As seen in
Figure 5, treatment of THP-1 cells with 8 mM NAM
resulted in an increase in intracellular NAD concentra-
tions, which peaks at 24 h, declines thereafter and
remains elevated up to 96 h. Strikingly, the ability of
NR (8 mM) to enhance intracellular NAD levels was
very similar to that seen of NAM. However, values
reached at 24 h were lower and did not decline there-
after. As expected, MNA did not induce a rise in intra-
cellular NAD concentrations. On the contrary, it even
led to a slight, but significant decrease.
Together these data demonstrate that NAM and
NR are metabolised to NAD and that a single dose is
sufficient to maintain a constant, elevated NAD con-
centration for up to 3 d. During the first 24 h the activ-
ity of NAD synthesising enzymes very likely prevails
that of NAD consuming enzymes (i.e. PARPs, CD38,
sirtuins) and at 48 h regeneration and maintenance of a
cellular NAD pool is reached.
Effect of NAM on SIRT1 and PARP1 expression
In light of the NAM-induced rise in intracellular NAD
levels, we determined expression levels of SIRT1 and



















































































Figure 2. Cell growth and apoptosis/necrosis of THP-1 cells
after treatment with NAM, NR, MNA and VitD. THP-1 cells
(0.2 106/ml) were treated with 8 mM NAM, 8 mM NR, 3.2 mM
MNA, 0.1 mM VitD or the respective solvent controls (ctrl). (a)
Determination of the cell number was performed 24 h, 48 h, 72
h and 96 h after treatment. Shown are the cell numbers SD
(n¼ 3). (b) After 96 h of treatment apoptosis/necrosis was
assessed by FITC Annexin V/PI staining. Shown are means of
apoptotic/necrotic cells [%] SD (n¼ 3). Statistics were per-
formed with the paired Student’s t-test calculated to the
respective control.
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course experiments (Figure 6a) showed that 24 h after
treatment with NAM, SIRT1 mRNA expression was
increased and that the values remained elevated up to
96 h. In line with the mRNA values, SIRT1 protein
expression (Figure 6b) was found to be slightly
increased at 48 h and 72 h in response to NAM.
Western blot analysis showed three bands, one of
them corresponding to the full-length protein
(120 kDa) whereas the faster migrating band very
likely belongs to an alternatively spliced isoform
recently described in mice.39
Unlike SIRT1, PARP1 mRNA (Figure 6c) did
not rise significantly until 96 h after incubation.
An increase of PARP1 protein could not be detected
at that time point (Figure 6d).
Effect of NAD metabolites on CD38, CD11b and
CD14 expression
To test whether NAM, NR and MNA were able
to induce monocytic differentiation, the expression of
classical monocytic differentiation markers such as
CD38, CD11b and CD14 was measured. As seen in
Figure 7, THP-1 cells express little CD11b and CD38
on their surface and CD14 is hardly detectable.
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Figure 3. Cell cycle analyses after treatment with NAM, NR and MNA. THP-1 cells (0.2 106/ml) were serum-starved (SS) for 48 h.
Upon addition of serum, the cells were cultured in the presence of NAM, 8 mM NR, 3.2 mM MNA or the respective solvent control
(ctrl) and cell cycle analyses were performed after 24 h and 48 h by flow cytometry. (a) One representative experiment of NAM
treated cells is shown. Cell cycle phases were defined by DNA staining with propidium iodide (PI). (b) Percentages of cells in G0/G1-
and S-phases. Shown are mean values SD (n¼ 3). Statistics were performed with the paired Student’s t-test calculated to the
respective control.
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Figure 4. Cell cycle analyses after treatment with NAM and resveratrol. THP-1 cells (0.2 106/ml) were serum-starved (SS) for 48
h. Upon addition of serum, the cells were cultured in the presence of 8 mM NAM and/or 10 mM resveratrol (Res) or the respective
solvent control (ctrl) and cell cycle analyses were performed after 48 h by flow cytometry. (a) One representative experiment is
shown. Cell cycle phases were defined by DNA staining with propidium iodide (PI). (b) Percentages of cells in G0/G1-, S- and G2/M-
phase. Shown are mean values SD (n¼ 3). Statistics were performed with the paired Student’s t-test calculated to the respec-
tive control.
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elevated in response to NAM while CD11b expression
was increased in MNA treated cells and CD38 levels
remained unaltered. Compared to the expression levels
of the three surface molecules induced by VitD, which
is well known to promote maturation of myeloid
cells,40–42 the effects on CD11b and CD14 are minor,
indicating an absence of maturation pressure.
NAD metabolites modulate the generation of ROS
and TNF-a production
A key feature of terminally differentiated myeloid cells
is their ability to eliminate pathogens by producing
a variety of toxic products including ROS. To test
whether THP-1 cells exposed to NAM, NR and
MNA display cellular functional responses that reflect
monocytic properties, we measured the production of
ROS in response to LPS. As demonstrated in Figure 8,
THP-1 cells treated with VitD for 96 h produce con-
siderable amounts of ROS when exposed to LPS.
A similar increase in ROS production was also seen
in response to treatment with NAM and NR. MNA
however caused a small decrease of ROS production
under the same experimental conditions.
In light of the importance of monocytic cells in
mounting a protective immune response against patho-
gens, which includes the release of pro-inflammatory
mediators, we tested whether NAM and its derivatives
influence the LPS-induced production of TNF-a, one
of the most prominent pro-inflammatory cytokines. As
illustrated in Figure 9a, treatment with LPS resulted in
an increase in TNF-a production which declined in
response to NAM, NR and MNA. Exposure to VitD
exerted similar effects (Figure 9b). Recent reports have
revealed a link between intracellular NAD levels and
LPS-induced TNF-a production in THP-1-derived
macrophages.43 To investigate whether such a link
exists in THP-1 cells, we determined both intracellular
NAD levels and TNF-a concentrations 96 h after treat-
ment with the NAD metabolites and after 4 h exposure
to LPS. Before adding LPS, the cells were taken up in
fresh media (without NAD metabolites) and the cell
numbers were adjusted. As seen in Figure 9c, adding
fresh media to either control or MNA pre-treated cells
had no effect on NAD concentrations whereas in
NAM and NR pre-treated cells NAD levels declined.
Independent of the presence of LPS identical NAD
concentrations were reached (Figure 9d), indicating
that LPS has no role in the NAM-, NR- and MNA-
mediated decrease in TNF-a production.
Given that CD14 and TLR4 are major players in
facilitating LPS-induced TNF-a production, we next
examined the influence of NAM and VitD on expres-
sion levels of the two cell surface proteins. We found
that CD14 and TLR4 are hardly detectable on the sur-
face of both stimulated and unstimulated THP-1 cells
and that treatment with VitD resulted in a strong up-
regulation of CD14 but had no effect on TLR4 expres-
sion (Figure 10). When exposed to NAM the expres-
sion levels of CD14 and TLR4 remained almost
unchanged (Figure 10). Thus, the two surface mole-
cules are unlikely to control the NAM-dependent
down-regulation of the LPS-induced TNF-
a production.
Discussion
It is well known that VitD induces immature leukaemia
cells to differentiate into mature monocytic cells40–42
and to cause macrophages to shift to a M2-pheno-
type.44 According to recent reports, the capability to
influence proliferation and differentiation processes
has also been attributed to another vitamin namely
vitamin B3 (niacin). Niacin-related compounds includ-
ing NAM have been shown to induce differentiation of
promyelocytic leukaemia HL-60 cells,45 and to regulate
retinoic acid (RA) and VitD induced differentiation
and cell cycle arrest of these cells.20 An inhibitory
effect of NAM on RA induced CD38 expression and
differentiation was described by Munshi et al.26 Studies
by Skokowa et al. revealed a decisive role of metabo-
lites of the NAD salvage pathway in G-CSF triggered
granulopoiesis.46
In contrast to NAM, information about NR and
MNA as potential modulators of proliferation and dif-
ferentiation are rare. NR has been mainly looked upon
as a compound enhancing oxidative metabolism and
protecting against metabolic and mitochondrial dis-


































Figure 5. NAD concentrations after treatment with NAM, NR
and MNA. THP-1 cells (0.2 106/ml) were treated with 8 mM
NAM, 8 mM NR, 3.2 mM MNA or the respective solvent control
(ctrl). NAD values were determined at 0 h, 24 h, 48 h, 72 h and
96 h and normalised to the total protein content. Shown are
means SD (n¼ 3). Statistics were performed with the paired
Student’s t-test calculated to the respective control.
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various applications, including treatment of hypertri-
glyceridemia,16,47 which contributes to cardiovascular
disease and reduced lifespan.47
We here show that all three NAD metabolites inhib-
it the proliferation of the myeloid cell line THP-1.
Growth attenuation was most pronounced in response
to NAM and equalled that induced by VitD. These
data are in line with publications describing NAM
as an agent that through down-regulation of SIRT1
activity inhibits proliferation of chronic lymphocytic
leukaemia and pancreatic cancer cells.48,49 The
NAM-induced reduction in proliferation was found
to be accompanied by activation of cell cycle arrest
via p53 and p21 expression,48 as well as by induction
of apoptosis.48,49 We did not observe any enhanced
apoptosis rate nor did we detect any p53 and p21 pro-
tein expression in THP-1 cells treated with or without
NAM (data not shown), indicating that retardation of
cell growth is most likely due to prolonged cell cycle
rather than to cell cycle arrest.
As NAM and NR lead to increased intracellular
NAD levels and cell cycle progression is regulated by
intertwined redox oscillators like NAD/NADH, it is
possible that, as suggested by da Veiga Moreira
et al.,50 intracellular NAD concentrations may influ-
ence the cell cycle phases.
NAD has emerged as an important mediator of
signalling mainly by serving as a substrate of
NAD-consuming enzymes such as SIRTs and
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Figure 6. SIRT1 and PARP1 expression after treatment with NAM. THP-1 cells (0.2 106/ml) were treated with or without 8 mM
NAM. After 24 h, 48 h, 72 h and 96 h mRNA values of (a) SIRT1 and (c) PARP1 were determined by real-time PCR. Data represent
mRNA levels of NAM-treated cells relative to the untreated control at each time point analysed (-NAM¼ 1, black bar) SD (n¼ 3).
(b) SIRT1 and (d) PARP1 protein were analysed by Western blot after 24 h, 48 h, 72 h, 96 h and 96 h, respectively. Densitometry data
of proteins were normalised to the corresponding b-actin control. Data represent protein levels of NAM-treated cells relative to the
untreated control at each time point analysed (-NAM¼ 100%, black bar) SD ((b) n¼ 3; (d) n¼ 4). Statistics were performed with
the paired Student’s t-test calculated to the respective control.
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deacetylation of an acetyl lysine residue, giving rise to
the deacetylated protein, NAM and O-acetyl-ADP-
ribose while the enzymatic cleavage of NAD by
PARPs results in formation of NAM and the transfer
of multiple ADPR-moieties to their specific target pro-
tein. Both enzyme families regulate fundamental events
such as apoptosis, cell-cycle progression, DNA repair
and transcription.51–54 They compete for the same
intracellular NAD-pool and NAM is a well-known
inhibitor of these NAD-depleting enzymes.7,55,56 The
relation between sirtuin and PARP activity is rather
complex. For example, activation of SIRT1 is associ-
ated with reduction of PARP1 activity whereas deletion
of SIRT1 increases the production of PAR (ADP-
ribose-polymer).7 In line with previous reports, we
here show that NAM and NR supplementation
enhance intracellular NAD-levels which remain elevat-
ed up to 96 h. NAM also induces the expression of
SIRT1 and PARP1 at the mRNA and SIRT1 only
weakly at the protein level. Although both enzymes
cleave NAD, the degradation seems to be compensated
by NAD synthesis so that steady state levels of NAD
are reached. Since growth retardation is not accompa-
nied by NAD depletion and independent of p21 and
p53, it might very well be related to the down-
regulation of other metabolic events such as pro-
tein synthesis.
In contrast to the here described tumour cell line,
NAM has been shown to accelerate cell proliferation of
human pluripotent stem cells.57 The authors speculate
that the effects of NAM on pluripotency may depend
on its role as a NAD precursor and on its ability to
enhance resistance to cellular stress.57 Enhanced DNA
synthesis and proliferation has also been shown to
occur in rat liver cells in response to MNA.58
MNA, by serving as a substrate for the enzyme
AOX1/GAD-3, has recently been described as a com-
pound able of generating a H2O2-mediated ROS signal








































































Figure 7. Expression of cell surface markers after treatment
with NAM, NR, MNA and VitD. THP-1 cells (0.2 106/ml) were
treated with 8 mM NAM, 8 mM NR, 3.2 mM MNA, 0.1 mM VitD
or the respective solvent control (ctrl). After 96 h the expres-
sions of the cell surface markers (a) CD11b, (b) CD14 and (c)
CD38 were measured by flow cytometry. Shown are mean
values of the median fluorescence intensity SD (n¼ 3).
Statistics were performed with the paired Student’s t-test























Ctrl Ctrl VitDNAM MNANR
Figure 8. ROS production after treatment with NAM, NR,
MNA and VitD. THP-1 cells (0.2 106/ml) were treated with
8 mM NAM, 8 mM NR, 3.2 mM MNA, 0.1 mM VitD or the
respective control (ctrl). After 96 h the cells (1 106/ml) were
stimulated with 100 ng/ml LPS for 30 min and intracellular ROS
production was measured by flow cytometry. Shown are the
percentages of the ROS (DCF)-positive cells SD (n¼ 3).
Statistics were performed with the paired Student’s t-test cal-
culated to the respective control.
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metabolic health.11 The authors speculate that sirtuins
play a key role in lifespan regulation by providing
increased amounts of the MNA precursor NAM.
Besides reducing proliferation of THP-1 cells, the
compounds also interfere with LPS-induced monocytic
properties like ROS and TNF-a production. While
NAM and NR stimulate ROS production in THP-1
cells, MNA, unlike in Drosophila,11 displayed inhibi-
tory effects. These dissimilar findings clearly reflect the
complexity of the biological functions of MNA and
significance of the experimental settings when defining
functional properties. Common to all three compounds
is their ability to inhibit LPS-induced TNF-a release.
Among immune cells, monocytes/macrophages which
are the major players of inflammatory processes are
especially susceptible to the anti-inflammatory action
of NAM.18,59 Based on recent data showing that LPS
caused a substantial increase in NAD levels and TNF-a
in pro-inflammatory (M1) macrophages but not in
anti-inflammatory (M2) macrophages, a link between
NAD levels and LPS-induced TNF-a release has been
suggested.43 We found that stimulation of THP-1 cells
with LPS (ctrl) resulted in an increase in TNF-a pro-
duction but had no effect on NAD concentrations. The
diminished TNF-a release in response to pre-treatment
with NAD metabolites was not associated with changes
in NAD levels induced by LPS.
Although TLR4 and CD14, two important mole-
cules facilitating LPS signalling, are expressed at very
low levels, they seem to be sufficient to initiate signal
transduction. Having shown that the NAM-induced
decrease in TNF-a production is not accompanied by
a diminished expression of CD14 and TLR4, we can
exclude a role of the two surface proteins in down-
regulating the inflammatory response. Suppression of
the TNF-a production is most likely regulated via
modulation of the transcription factors NF-jB and
FoxO3.17,60,61
Taken together our data clearly indicate that NAM




































































































Figure 9. LPS-induced TNF-a production and NAD-content. THP-1 cells (0.2 106/ml) were treated with (a) 8 mM NAM, (c) 8 mM
NR, (d) 3.2 mM MNA and (b) 0.1 mM VitD or the respective control (ctrl). After 96 h the cells (1 106/ml) were incubated for
further 4 h in the absence and presence of 100 ng/ml LPS. (a, b) TNF-a concentrations in the supernatants were measured by ELISA.
Shown are mean values SD ((a) n¼ 6; (b) n¼ 3). NAD values of (c) unstimulated and (d) LPS-stimulated cells were normalised to
the total protein content. Shown are means SD (n¼ 3). Statistics were performed with the paired Student’s t-test calculated to the
respective control.
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the methylation product of NAM, have the potential to
retard the proliferation of a myeloid leukaemia cell line
by arresting the cells in G0/G1-phase. Apart from their
anti-proliferative properties, the compounds exert anti-
inflammatory effects and especially NAM and NR
prime the cells to generate ROS. Although the retarda-
tion of proliferation is not accompanied by differenti-
ation into functional mature cells, vitamin B3 and its
derivatives strongly influence immunological properties
of monocytic cells.
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